SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union#SpringWorks #Therapeutics #Announces #Expected #CHMP #Opinion #Nirogacestat #Treatment #Adults #Desmoid #Tumors #European #Union